Kornimate/medical-research-clean huggingface dataset:
contemporary restorative materials in primary molars

Conditions: Dental Caries

Summary: this randomized controlled trial aims to compare the clinical effectiveness of four ion-releasing restorative materials in the proximal cavities of primary molars that underwent selective caries removal. the main questions to answer are: * will there be any difference among the restorative materials clinical succes in the means of modified united states public health services (usphs) criteria for dental restorations? * will there be any difference among the restorative materials in the means of preservation of pulpal vitality? eighty six children (262 teeth), between 5 and 9 years old (7.15±1.14) enrolled for the study. researchers will compare the clinical performance of restorative materials, (1:equia forte ht; 2: fuji ii lc; 3: cention n; 4: chemfil rock), applied to the proximal cavities of primary molars following selective caries removal, according to the modified usphs criteria. participants will: - visit the clinic 1st,3rd,6th,12th,18th,24th,30th and 36th months after the restoration.


Eligibility criteria:
inclusion criteria: for participants: * no known or suspected history of allergy to medications or restorative materials * no habits of teeth grinding or clenching * presence of at least one interproximal carious lesion for teeth: * carious lesion reaching at least 1/2 dentin * in contact with adjacent teeth and in occlusion with antagonist teeth * have no pathological mobility * periodontally healthy * no symptoms of pulpal pathology * physiological root resorption should not exceed one-third of the root length if seen * permanent tooth germ present below the tooth exclusion criteria: * did not attend their follow-up appointments

Keywords: cention n resin-modified glass-ionomer cement hybrid glass-ionomer cement zinc reinforced glass-ionomer cement primary molar teeth
ibuprofen plus acetaminophen versus oxycodone alone after hand surgery

Conditions: Carpal Tunnel Syndrome; Dupuytren Contracture; Trigger Digit; Ganglion Cysts; De Quervain Disease

Summary: this study is about pain control and medication following outpatient soft-tissue hand surgery. we hope to learn if ibuprofen and acetaminophen will achieve similar pain relief and satisfaction when compared with oxycodone alone.

opiate analgesics remain the most popular option following outpatient hand surgery despite growing evidence that non-opiate analgesics may provide equivalent pain relief with fewer adverse effects and greater overall satisfaction. the purpose of this randomized trial is to compare the efficacy, side effect profiles and satisfaction associated with ibuprofen plus acetaminophen versus oxycodone alone following outpatient hand surgery. no previous studies have compared the use of opiate analgesics with acetaminophen/ibuprofen following outpatient hand surgery. patients will be randomized to receive either oxycodone alone or acetaminophen and ibuprofen following outpatient soft tissue hand surgery. patients will be randomized to receive one of the two aforementioned pain regimens. patients will be given a booklet in which to record pain level by visual analog scale (vas), satisfaction with pain control, brief pain inventory and any side effects. patients will be seen in clinic 1 week after surgery to review symptoms. patients may also be contacted by phone to review daily log of symptoms. patients will be seen in clinic 1 week after surgery per standard of care.

Eligibility criteria:
inclusion criteria: * age greater than 18 years * scheduled to undergo elective outpatient soft tissue hand surgery for one of the following procedures: carpal tunnel release, dupuytren contracture release, trigger digit release, ganglion cyst removal, de quervain's release. * primary language is english or spanish exclusion criteria: * any pre-existing condition requiring preoperative opiate analgesia, eg chronic pain syndrome * allergy to acetaminophen, ibuprofen, or oxycodone * renal impairment or liver disease either documented based on history or when preoperative creatinine, bun, or liver function tests are outside the normal range provided by the lab * peptic ulcer disease or any history of gastrointestinal bleeding * coagulopathy documented on history, review of systems, or based on preoperative lab testing where pt, ptt, or inr are outside the normal range provided by the lab * pregnancy based on positive beta-hcg test which is performed on the day of the surgical procedure as is standard protocol

Keywords: oxycodone ibuprofen acetaminophen soft-tissue hand surgery carpal tunnel release dupuytren contracture release trigger digit release ganglion cyst removal de quervain's release
changes of muramyl dipeptide in intestinal and extra-intestinal diseases

Conditions: Colorectal Cancer; Inflammatory Bowel Disease; Atherosclerotic Cardiovascular Disease; Type2 Diabetes Mellitus

Summary: nucleotide-binding oligomerization domain 2 (nod2) signaling is critical for human health.to figure out the clinical relevance of nod2 ligands, the investigators plan to evaluate the change of nod2 ligands in inflammatory bowel diseases (ibd), crc, atherosclerotic cardiovascular disease (acvd), and type 2 diabetes mellitus (dm2 ).

previous studies have shown that nod2 gene mutants were associated with the crohn's disease (cd), colorectal cancer (crc) and many other diseases, suggesting the critical role of nod2 signaling in human physiology and pathogenethesis. however, whether decreased nod2 ligands also contributed to these diseases is unknown. in this study, the investigators plan to evaluate the change of nod2 ligands in inflammatory bowel diseases (ibd), crc, atherosclerotic cardiovascular disease (acvd), and type 2 diabetes mellitus (dm2 ). for each of the patient, a sex- and age- matched control were chosen. both the targeted metabolomics (lc-ms-ms methods) and nod2-transfected cells co-expressing nf-κb luciferase reporters were used to test nod2 ligands in the fecal and plasma samples.

Eligibility criteria:
inclusion criteria: 1. males or females at least 18-70 years old. 2. patient able to give informed consent. 3. patient with biopsy-proven crc 4. patient with biopsy-proven crohn's disease (cd) or ulcerative colitis(uc), in the active phase. 5. patients with clinical diagnosed dm2 6. patients with acvd:coronary angiography more than 50% stenosis in single or multiple vessels. 7. the age- and sex- matched health controls for each patient. exclusion criteria: 1.use antibiotics or probiotics within the last 2 weeks.

Keywords: nod2 ligands
assessment of cancer concerns at the end of treatment (ace)

Conditions: Breast Cancer(BC) Survivors

Summary: this study will describe patient-reported symptom burden and concerns, quality of life (qol), and health behaviors of breast cancer(bc) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (pro) data, and evaluate provider satisfaction following delivery of an electronic health record (her)/epic summary of these pros. secondary aims will estimate differences in referral to available services between those providers exposed to the pro summary and historical controls. bc survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (eot)/survivorship focused visit will be the focus of this study.


Eligibility criteria:
inclusion criteria: 1. diagnosed with invasive, non-metastatic bc (stage i, ii, or iii) without hematogenous or distant metastases 2. have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). may still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase inhibitors). 3. within 1 year of completing primary treatment 4. scheduled for an eot visit 5. age 18 years or older 6. can understand written english 7. have internet access and a working email address exclusion criteria: 1. diagnosed with non-invasive (stage 0/dcis) or metastatic (stage iv) cancer or hematogenous or distant metastatic disease 2. no working email address -
the effects of minimal enteral nutrition on mesenteric blood flow and oxygenation in neonates with hie

Conditions: Hypoxic-Ischemic Encephalopathy

Summary: the goal of this clinical trial is to evaluate the effects of minimal enteral nutrition (men) on mesenteric blood flow and oxygenation with doppler usg and near infrared spectroscopy (nirs) during therapeutic hypo¬thermia (th) in babies with hypoxic ischemic encephalopathy. the main question it aims to answer is: 1- how do the mesenteric blood flow and oxygenation get affected with men during th? participants will be either fed with men during th or given placebo.

objectives: the investigators aimed to evaluate the effects of minimal enteral nutrition (men) on mesenteric blood flow and oxygenation with doppler usg and near infrared spectroscopy (nirs) during therapeutic hypo¬thermia (th) in babies with hie. methods: this prospective, randomized controlled study was conducted between september 2020 to august 2022. the infants receiving men during hypothermia (n =30) and those who were not fed (n=30) constituted the study and control groups. infants were monitored continuously with nirs and mesenteric arterial blood flow velocities were measured with doppler usg before and after feeding.

Eligibility criteria:
inclusion criteria: * the neonates with evidence of encephalopathy de¬fined by seizures or abnormalities on a modified sarnat exam were enrolled. the hypoxic-ischemic injury was defined by 1. a ph of ≤ 7.0 and/or 2. base deficit \&gt;-16 mmol/l recorded in cord blood or blood gas obtained within the first hour postnatally or a ph of 7.0 - 7.15 and/or base deficit (-10-15.9) mmol/l with the presence of an acute perinatal event (cord prolapse, placental abruption, heart rate decelerations, severe fetal bradycardia). in cases where criteria 1 or 2 are met, with the presence of seizures or a diagnosis of moderate to severe encephalopathy according to the sarnat \&amp; sarnat classification based on neurological examination were treated with th. exclusion criteria: * infants with congenital malformation or hereditary metabolic diseases, infants whose enteral feeding was initiated before randomization and infants without lack of parental consent were excluded. the maternal and neonatal demographic characteristics and clinical outcomes were collected from medical records.

Keywords: therapeutic hypothermia minimal enteral nutrition mesenteric oxygenation mesenteric blood flow splanchnic oxygenation cerebrosplanchnic ratio
safety and immunological effect of pembrolizumab in resectable or borderline resectable pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this clinical trial is to study an experimental drug called pembrolizumab or mk-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline resectable pancreatic cancer. in general, pancreatic cancer that cannot be removed by surgery is sometimes treated with chemotherapy and radiation therapy, called neoadjuvant treatment, to shrink the tumor so that surgery might be possible. however, this is not always effective at shrinking the tumor enough to allow it to be removed with surgery. recent discoveries suggest that the investigators own immune system might have a role in controlling the growth of tumors. drugs such as pembrolizumab can stimulate the immune system against cancer. the purpose of this study is to investigate whether pembrolizumab can be used safely during neoadjuvant treatment and can improve the body's immune response against pancreatic cancer. pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is not approved by the u.s. food and drug administration (fda) for this purpose.


Eligibility criteria:
inclusion criteria: 1. measurable disease based on response evaluation criteria in solid tumors (recist) 1. 2. performance status of 0 or 1 on the eastern cooperative oncology group (ecog) performance scale 3. adequate organ function 4. in subjects requiring biliary decompression, metal stent or drainage using percutaneous transhepatic cholangiogram (ptc) are allowed exclusion criteria: 1. immunodeficiency or taking steroid or any other form of immunosuppressive therapy 2. has a plastic biliary stent for decompression 3. metastatic disease 4. prior treatment for pancreatic cancer (other than 4-8 cycles of folfirinox) or prior treatment with radiation for other diagnoses to the expected pancreatic cancer treatment area 5. active autoimmune disease 6. pregnancy or nursing 7. known history of human immunodeficiency virus (hiv) or hepatitis b or c 8. prior monoclonal antibody within 4 weeks prior to study day 1 9. known additional malignancy that is progressing or requires active treatment 10. evidence of interstitial lung disease or active, non-infectious pneumonitis 11. active infection requiring systemic therapy 12. prior therapy with an anti-program death (pd-1) antibody, anti-pd-l1, anti-pd-l2, or anti-cytotoxic t-lymphocyte-associated antigen-4 (ctla-4) antibody

Keywords: immunotherapy neoadjuvant resectable borderline resectable
chiropractic spinal manipulative therapy for acute sciatica secondary to lumbar disc herniation

Conditions: Acute Sciatica; Lumbar Disc Herniation

Summary: comparisons of surgical and non-operative treatment of patients with acute sciatica secondary to lumbar intervertebral disc herniation (as/ldh) have shown no appreciable difference in outcome. the composition of the non-operative treatment of this patient population remains poorly defined. spinal manipulative therapy (smt) has demonstrated value in the treatment of as/ldh. recent preliminary studies suggest that smt provides therapeutic benefit through the modulation of in vivo inflammatory mediators. this feasibility study will define the key experimental variables required to conduct a large multicentre study that will clarify the biological and clinical outcomes of smt in the treatment of patients with as/ldh.


Eligibility criteria:
inclusion criteria: * chief complaint of sciatica rather than lower back pain * pain of up to 6 months' duration * a mcculloch criteria score of 5/5 (two clinical symptoms and two clinical signs of sciatica, and diagnostic imaging confirming the presence of a herniated nucleus pulposus contacting a spinal nerve root at the appropriate level) * fluency in spoken and written english to ensure subjects understand the content of questionnaires and consent exclusion criteria: * progressive neurological deficit * spinal fracture * spinal tumor * spinal infection * spinal nerve root motor score of less than 4/5 * spinal stenosis that is not attributable to a herniated disc * any other significant spinal ailment or local or generalized co-morbidity ailment that could affect outcomes independently of smt ( e.g. seronegative spondyloarthropathy, malignancy).

Keywords: chiropractic manipulation radiculopathy sciatica lumbar disc herniation protrusion
a phase 2/3 multicenter, controlled trial of rhbmp-2/cpm in tibial fractures

Conditions: Fractures

Summary: the primary objective of this study is to assess whether a single dose of rhbmp-2/cpm administered at the fracture site via percutaneous injection, in combination with standard of care, accelerates fracture union and return to normal function in subjects who have a closed diaphyseal tibial fracture when compared to standard of care alone.


Eligibility criteria:
inclusion criteria: * skeletally mature, male and female subjects who are at least 18 years old. * closed diaphyseal tibial fracture. * closed reduction and definitive internal fixation by means of a reamed, locked intramedullary nail within 72 hours after injury. exclusion criteria: * concurrent fractures of the ipsilateral or contralateral lower extremity other than the ipsilateral fibula, that would impede performance on the functional assessment of weight bearing. * planned procedure(s) to stimulate fracture healing after intramedullary nailing. * neurovascular impairment of the fractured limb, deep vein thrombosis, or (impending) compartment syndrome.
metabolomics dynamics study for severe patient

Conditions: Age:18-70 Years; Acute Severe Disease; Acute Physiology And Chronic Health Evaluation(APACHE)II>10

Summary: acute severe disease is a major public health challenge that often affects young adults.in past decade, there are lot of new techniques have been developed that aim to improve the outcome of acute severe disease, but few of these works success. according to recently studies, the mortality of the multiple organ dysfunction syndrome（mods) that is the major cause of death in patients who suffering from acute severe disease, is not improved. on the contrary, if mods be predicted in early stage of acute severe disease, the death can be prevented. because acute severe disease poses complex injury that involves multiple pathological processes, understanding the cellular and metabolic network malfunction during acute severe disease is crucial for clinical monitoring and intervention. human metabolism is a complex network with hundreds of cross-linked paths. during critical illness, the metabolic network is dynamically disturbed at multiple points. classical research typically isolates a small part of this network to investigate the impact of pathological physiology molecular mechanisms on clinical outcome. in particular, researchers have examined metabolic disturbances such as cytokine network dysfunction, skeletal muscle breakdown, insulin resistance, dyslipidemia, testosterone and growth hormone/insulin like growth factor （igf）dysfunctions, low thyroxine syndrome, and deficiency of vitamin d and calcium with secondary hyperparathyroidism. these complex metabolic disturbances appear and interact at different stages during the pathological process after acute severe illness. therefore, an integrated approach that combines the biochemical/molecular changes with network disturbances is the key to understanding acute severe illness at the systems biology level and establishing an accurate quantitative model for clinical monitoring. an interdisciplinary method that includes high-throughput quantitative techniques and effective mathematical and visualization tools is necessary. furthermore, interdisciplinary methods present the opportunity to develop innovative clinical diagnosis and monitoring methods for severe injuries. the aim of this study is to provide a novel high-throughput method that integrated proton-nuclear magnetic resonance (nmr) metabolomic fingerprinting and high performance liquid chromatography with advance mathematics tools to modeling metabolic dynamics after acute severe disease.


Eligibility criteria:
inclusion criteria: * age:18-70 years * acute physiology and chronic health evaluation(apache)ii\>10 exclusion criteria: * with comorbidity (diabetes,hyperthyroidism or primary organ dysfunction ) * pregnancy

Keywords: acute severe disease intensive care unit adult cohort study metabolomics nmr high performance liquid chromatography
leukotriene receptor antagonists or steroids in pre-school asthma

Conditions: Asthma

Summary: explorative comparison of montelukast with inhaled steroids (fluticasone) to estimate responder profiles, in terms of symptom scores, rescue medication, increase of fev1, in correlation to presence of allergy, bronchial hyperreactivity (pd20), exhaled no, excretion of leukotrienes, response to raba and laboratory parameters in patients with pre-school asthma i.e. asthma phenotypes.


Eligibility criteria:
inclusion criteria: * male or female patients age 4 -6 years * diagnosis of mild intermittent bronchial asthma (step i-ii) in the past 6 - 12 months as stated by the investigator: * use of inhaled beta-2-agonists \< 1/week (max 3 puff /d) * exacerbation-free interval \> 4 weeks prior to visit 1 * the written informed consent of parents after received written and oral information about the aim, purpose and risks of the study must be present exclusion criteria: * asthma severity ≥ step 2 * severe concomitant diseases * suspected non-compliance * age below 4 and age above 7 years * last study participation \< 30 days

Keywords: pre-school asthma responder profiles fluticasone montelukast leukotriene children with pre-school asthma
multifamily psychoeducation and cognitive remediation for recent-onset psychosis

Conditions: Recent-Onset Psychosis; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder With Psychotic Features; Major Depression With Psychotic Features; Psychotic Disorder Not Otherwise Specified (NOS)

Summary: the goal of this study is to determine whether pairing multifamily group psychoeducation with cognitive remediation may facilitate improved outcomes among individuals with recent-onset psychosis.


Eligibility criteria:
inclusion criteria (individual with recent-onset psychosis): * diagnosis of a non-substance induced psychotic disorder per dsm-iv-tr criteria determined using the structured clinical interview for the dsm-iv. * age between 18-35 * willing to participate in interventions at university of arizona medical center, south campus * willing to complete research assessments * duration of psychotic symptoms of less than 5 years determined using the symptom onset in schizophrenia inventory * able to provide informed consent * fluent in english * must have a family caregiver who is willing to participate in the study * willing to allow videotaping of multifamily group therapy sessions. * no evidence of mental retardation as defined as never having qualified to receive services from the arizona department of economic security, division of developmental disabilities. exclusion criteria (individual with recent-onset psychosis): * failure to meet inclusion criteria inclusion criteria (caregiving relative of individual with recent-onset psychosis): * must be someone that the individual with recent-onset psychosis identifies as providing support and care to the individual with recent-onset psychosis. does not need to be a biological relative. * must spend considerable time with the individual with recent-onset psychosis as defined at 10 hours or more of direct contact per week. * willing to participate in participate in family intervention at university of arizona medical center, south campus for 2 years * willing to complete research assessments * able to provide informed consent * fluent in english * willing to allow videotaping of multifamily group sessions. exclusion criteria (caregiving relative of individual with recent-onset psychosis): * failure to meet inclusion criteria

Keywords: first-episode psychosis cognitive remediation family psychoeducation